TISIDB

Summary
Symbol	ENO1
Name	enolase 1, (alpha)
Aliases	PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Cell membrane Cytoplasm, myofibril, sarcomere, M line Note=Can translocate to the plasma membrane in either the homodimeric (alpha/alpha) or heterodimeric (alpha/gamma) form. ENO1 is localized to the M line.; SUBCELLULAR LOCATION: Isoform MBP-1: Nucleus.
Domain	PF00113 Enolase PF03952 Enolase
Function	Multifunctional enzyme that, as well as its role in glycolysis, plays a part in various processes such as growth control, hypoxia tolerance and allergic responses. May also function in the intravascular and pericellular fibrinolytic system due to its ability to serve as a receptor and activator of plasminogen on the cell surface of several cell-types such as leukocytes and neurons. Stimulates immunoglobulin production.; FUNCTION: MBP1 binds to the myc promoter and acts as a transcriptional repressor. May be a tumor suppressor.

> Gene Ontology [ TOP ]
Biological Process	GO:0001558 regulation of cell growth GO:0005996 monosaccharide metabolic process GO:0006006 glucose metabolic process GO:0006007 glucose catabolic process GO:0006090 pyruvate metabolic process GO:0006091 generation of precursor metabolites and energy GO:0006094 gluconeogenesis GO:0006096 glycolytic process GO:0006165 nucleoside diphosphate phosphorylation GO:0006732 coenzyme metabolic process GO:0006733 oxidoreduction coenzyme metabolic process GO:0006734 NADH metabolic process GO:0006735 NADH regeneration GO:0006757 ATP generation from ADP GO:0009116 nucleoside metabolic process GO:0009119 ribonucleoside metabolic process GO:0009123 nucleoside monophosphate metabolic process GO:0009126 purine nucleoside monophosphate metabolic process GO:0009132 nucleoside diphosphate metabolic process GO:0009135 purine nucleoside diphosphate metabolic process GO:0009141 nucleoside triphosphate metabolic process GO:0009144 purine nucleoside triphosphate metabolic process GO:0009150 purine ribonucleotide metabolic process GO:0009161 ribonucleoside monophosphate metabolic process GO:0009167 purine ribonucleoside monophosphate metabolic process GO:0009179 purine ribonucleoside diphosphate metabolic process GO:0009185 ribonucleoside diphosphate metabolic process GO:0009199 ribonucleoside triphosphate metabolic process GO:0009205 purine ribonucleoside triphosphate metabolic process GO:0009615 response to virus GO:0016049 cell growth GO:0016051 carbohydrate biosynthetic process GO:0016052 carbohydrate catabolic process GO:0019318 hexose metabolic process GO:0019319 hexose biosynthetic process GO:0019320 hexose catabolic process GO:0019362 pyridine nucleotide metabolic process GO:0019674 NAD metabolic process GO:0030308 negative regulation of cell growth GO:0042278 purine nucleoside metabolic process GO:0044282 small molecule catabolic process GO:0044283 small molecule biosynthetic process GO:0044723 single-organism carbohydrate metabolic process GO:0044724 single-organism carbohydrate catabolic process GO:0045926 negative regulation of growth GO:0046031 ADP metabolic process GO:0046034 ATP metabolic process GO:0046128 purine ribonucleoside metabolic process GO:0046364 monosaccharide biosynthetic process GO:0046365 monosaccharide catabolic process GO:0046496 nicotinamide nucleotide metabolic process GO:0046939 nucleotide phosphorylation GO:0051186 cofactor metabolic process GO:0061615 glycolytic process through fructose-6-phosphate GO:0061620 glycolytic process through glucose-6-phosphate GO:0061621 canonical glycolysis GO:0061718 glucose catabolic process to pyruvate GO:0072524 pyridine-containing compound metabolic process GO:1901657 glycosyl compound metabolic process
Molecular Function	GO:0000287 magnesium ion binding GO:0004634 phosphopyruvate hydratase activity GO:0016829 lyase activity GO:0016835 carbon-oxygen lyase activity GO:0016836 hydro-lyase activity GO:0045296 cadherin binding GO:0050839 cell adhesion molecule binding GO:0051020 GTPase binding GO:0098631 protein binding involved in cell adhesion GO:0098632 protein binding involved in cell-cell adhesion GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component	GO:0000015 phosphopyruvate hydratase complex GO:0005913 cell-cell adherens junction GO:0030016 myofibril GO:0030017 sarcomere GO:0031430 M band GO:0031672 A band GO:0043292 contractile fiber GO:0044445 cytosolic part GO:0044449 contractile fiber part

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa03018 RNA degradation hsa04066 HIF-1 signaling pathway hsa00010 Glycolysis / Gluconeogenesis hsa01100 Metabolic pathways hsa01200 Carbon metabolism hsa01230 Biosynthesis of amino acids
Reactome	R-HSA-70263: Gluconeogenesis R-HSA-70326: Glucose metabolism R-HSA-70171: Glycolysis R-HSA-1430728: Metabolism R-HSA-71387: Metabolism of carbohydrates

Summary
Symbol	ENO1
Name	enolase 1, (alpha)
Aliases	PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ENO1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between ENO1 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
29308319	Pancreatic Carcinoma; Lung Carcinoma	Promote immunity	Citrullinated α-enolase is an effective target for anti-cancer immunity.
23333712	pancreatic carcinoma	Promote immunity	In a genetic model of pancreatic carcinoma, vaccination with ENO1 DNA elicits humoral and cellular immune responses against tumors, delays tumor progression, and significantly extends survival

Summary
Symbol	ENO1
Name	enolase 1, (alpha)
Aliases	PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ENO1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ENO1
Name	enolase 1, (alpha)
Aliases	PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ENO1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.632	0.072
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.72	0.873
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.56	0.859
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.293	0.531
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.22	0.939
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.393	0.919
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.093	0.879
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.2	0.942
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.45	0.881
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.292	0.932
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.186	0.972
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.143	0.173

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ENO1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	2.7	1	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.4	0.3	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ENO1
Name	enolase 1, (alpha)
Aliases	PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ENO1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ENO1
Name	enolase 1, (alpha)
Aliases	PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ENO1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ENO1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ENO1
Name	enolase 1, (alpha)
Aliases	PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ENO1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ENO1
Name	enolase 1, (alpha)
Aliases	PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ENO1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ENO1
Name	enolase 1, (alpha)
Aliases	PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ENO1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ENO1
Name	enolase 1, (alpha)
Aliases	PPH; ENO1L1; MPB1; NNE; MYC promoter-binding protein 1; alpha enolase like 1; enolase-alpha; non-neural enol ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ENO1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting ENO1.

ID	Name	Drug Type	Targets	#Targets
DB01593	Zinc	Small Molecule	A1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......	119
DB09130	Copper	Small Molecule	A1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......	141
DB11638	Artenimol	Small Molecule	ACTG1, ALB, ALDH7A1, ALDOA, ANXA2, ATP5A1, ATP5L, ATP5O, CAST, CCT ......	79

Browse ENO1